# Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

> **NCT01092182** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 194 (actual)

## Conditions studied

- Burkitt Lymphoma
- Diffuse Large B-cell Lymphoma, c-MYC Positive
- Plasmablastic Lymphoma

## Interventions

- **DRUG:** EPOCH-R
- **DRUG:** EPOCH-RR

## Key facts

- **NCT ID:** NCT01092182
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-25
- **Primary completion:** 2020-09-30
- **Final completion:** 2023-02-16
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01092182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01092182, "Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01092182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*